Last reviewed · How we verify
NCT05492565: SeVIHPrEP
Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis
trial testing Tenofovir Disoproxil Fumarate 300 MG Oral Tablet in HIV Infection Primary in 500 participants. Enrolling by invitation.
31 December 2029
Quick facts
| Lead sponsor | Hospitales Universitarios Virgen del Rocío |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 January 2020 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Tenofovir Disoproxil Fumarate 300 MG Oral Tablet — full drug profile →
Conditions studied
- HIV Infection Primary — all drugs for HIV Infection Primary →
- Hepatitis, Viral, Human — all drugs for Hepatitis, Viral, Human →
- Sexually Transmitted Infections, Excluding HIV and Hepatitis — all drugs for Sexually Transmitted Infections, Excluding HIV and Hepatitis →
Sponsor
Hospitales Universitarios Virgen del Rocío
Who can join
18 and older, any sex, with HIV Infection Primary or Hepatitis, Viral, Human. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pre-exposure prophylaxis (PrEP) based on tenofovir represents a considerably new preventive intervention that has shown to significantly decrease the number of HIV infections while it enables early diagnosis of HIV and other sexually transmitted diseases (STI). In Southern Spain, the target population to receive PrEP are men who have sex with men (MSM) with a history of STI and who pursue high-risk sexual practices regarding the acquisition of HIV, including an elevate number of sex partners, no or inconsistent condom use and the use of specific recreational drugs in the context of sexual activity ("chemsex"). Despite the benefits of PrEP use, it must be taken into consideration that risk compensations that may facilitate the acquisition of other STI may occur, including a higher implementation of risk practices and an increase in the number of partners, which is made easy as various social networks designed for this purpose are available nowadays. In order to better understand the benefit/drawback ratio, accurate data of a population using PrEP under real-life conditions, with densely scheduled follow-up and well-characterized (socio-)demographic parameters, sexual behaviour and STI are warranted.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05492565
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
Trials testing the same drug.
- NCT04237376 — Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Vertical Transmission · unknown
Other recruiting trials for HIV Infection Primary
Currently open trials in the same condition.
- NCT06872307 — Intervention to Enhance PrEP Persistence · NA · recruiting
- NCT05947266 — Intervening With Haitian Immigrants in the U.S. to Improve HIV Outcomes · NA · recruiting
- NCT04663152 — Integrated Navigation Services for Treatment Adherence, Counseling, and Research · NA · recruiting
Other Hospitales Universitarios Virgen del Rocío trials
Trials by the same sponsor.
- NCT07324447 — EFFECTS OF SUPERVISED PHYSICAL EXERCISE AFTER BARIATRIC SURGERY ON MUSCLE MASS AND BONE DENSITY (OBEFIT STUDY) · NA · recruiting
- NCT07175012 — ELECTROVEST: Electro-Stimulation Vibratory Vest for Pulmonary Rehabilitation in Patients With Chronic Respiratory Diseas · NA · completed
- NCT05766215 — Nurse-led Therapeutic Education Effects in Glycemic Control and Knowledge of Type 1 Diabetes Mellitus Patients Under Hos · NA · unknown
- NCT05159843 — Effects of Nursing Diabetes Self-management Education · NA · unknown
- NCT05633927 — Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05492565 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospitales Universitarios Virgen del Rocío
- Last refreshed: 22 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05492565.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing